ff_relativeren schreef op 8 juni 2020 14:14:
[...]
Het gaat om dit document van Kiadis Pharma :
ir.kiadis.com/static-files/e93262f7-4... ,
en dan verwijs ik naar deze citaten inclusief bladzijde-verwijzing :
Deze quote staat onderaan bladzijde 53 en bovenaan bladzijde 54.
Based on our operating plans in relation to our NK-platform and programs (see Chapter 4) and also in view of the discontinuation of our ATIR activities, we believe that
existing cash and cash equivalents will allow us to continue operating the business into the fourth quarter of 2020 and accordingly we will need to raise additional financing in advance of that time,
by raising further equity, convertible financing or non-dilutive financing such as debt financing arrangements, strategic transactions or other means.
We may also delay, reduce the scope of, eliminate or divest clinical programs, partner with others or divest one or more of our activities, and consider other cost reduction initiatives, such as withholding initiation or expansion of clinical trials or research, and slowing down patient recruitment of clinical trials.
In the event we are not be able to generate sufficient funds from these measures, we may be unable to continue as a going concern, our business, financial condition and/or results of operations could be materially and adversely affected and we may ultimately go into insolvency – see also Note 2 of the Full Year Financial Statements.
En deze quote is te lezen bovenaan bladzijde 103 van hetzelfde document (bij het missen van 1 termijnbetaling) :
"Further to the abovementioned 1,513,052 newly issued Shares, the former holders of CytoSen shares have a conditional entitlement to receive 267,012 newly issued Shares - the Holdback Shares as further discussed below. Also, as per the CytoSen Acquisition Agreement, the former holders of CytoSen shares and options are eligible to potential future consideration of up to 5,819,466 additional Shares upon the achievement of six clinical development and regulatory milestones, with the final milestone being first FDA approval of an NK-cell product based on CytoSen's technology.
In the event we fail to pay any contingent consideration due, a party that has a competing NK-cell product in clinical development or on the market would acquire control over us, we sell all or substantially all our assets, or we transfer our NK-cell related intellectual property to a third party, all unpaid contingent consideration in Shares will become immediately payable at a reduced amount that will be calculated according to a pre-agreed formula that is based on the moment of the accelerated payment of the contingent consideration compared to the projected timing of such payment on an unaccelerated basis. In the event that anyone acquires 50% or more of the voting rights attached to our outstanding Shares, we dispose a majority of our assets, or are party to a merger, reorganization or consolidation which results in the voting rights attached to our Shares immediately prior to such transaction representing less than 50% of the voting rights of the surviving entity or its parent immediately after such transaction, we have the right to immediately pay all unpaid contingent consideration in Shares at a reduced amount that will be calculated according to the abovementioned pre-agreed formula."